tbuckley/cabot-search huggingface dataset:
Errata
Authors: K Meyer, M Landthaler, E Geissinger, C Hafner
Journal: British Journal of Dermatology (2014)

British Journal of DermatologyVolume 170, Issue 6 p. 1382-1382 ErratumFree Access Errata This article corrects the following: Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network J.M.P.A. Reek, P.P.M. Lüumig, M.E. Otero, J. Zweegers, P.C.M. Kerkhof, P.M. Ossenkoppele, M.D. Njoo, J.M. Mommers, M.I.A. Koetsier, W.P. Arnold, B.A.M. Sybrandy-Fleuren, A.L.A. Kuijpers, M.P.M. Andriessen, M.M.B. Seyger, W. Kievit, E.M.G.J. Jong, Volume 170Issue 5British Journal of Dermatology pages: 1158-1165 First Published online: May 19, 2014 First published: 19 June 2014 https://doi.org/10.1111/bjd.13140AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat In the article by van den Reek et al1, the second author's name was published wrong. The correct name appears below: P.P.M. van Lümig References 1van den Reek JMPA, van Lümig PPM, Otero ME et al. Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network. Br J Dermatol 2014; 170: 1158– 65. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar Volume170, Issue6June 2014Pages 1382-1382 ReferencesRelatedInformation
In Reply:
Authors: Eveline S.J.M. De Bont, Claudi Oude Nijhuis, Jourik A. Gietema, Winette T.A. Van der Graaf, Simon M.G.J. Daenen, Edo Vellenga, Els M. TenVergert, Karin M. Vermeulen, Harrie J.M. Groen, Willem A. Kamps
Journal: Journal of Clinical Oncology (2006)

not the first to take on this challenge, they may be the first to select a management option for low-risk patients with FN that includes no empiric antibiotics for presumed infection.On the basis of a high mortality rate when early antibiotic therapy is withheld, the Infectious Diseases Society of America recommends a course of empiric therapy until recovery from the neutropenia and fever. 2 However, patients with FN have a wide variation in the duration of neutropenia, time to defervescence, hospitalization length of stay, and mortality.Previous efforts to identify low-risk patients with FN who may be candidates for ambulatory treatment or oral antibiotics have been limited by high false-negative and false-positive rates. 3he authors of this study offer another approach to identifying low-risk patients with FN who might need less aggressive treatment or perhaps no treatment at all.Although interleukin-8 is not clinically available outside of a research setting, if the results of this study are confirmed and validated, this could offer a safe and less expensive approach to managing low-risk patients with FN.However, before there is a leap to this potentially risky approach to treating patients with FN, it is important to make note of the substantial methodologic limitations of this study.It is important to emphasize that half of the patients in this study were children, who experience significantly less morbidity and mortality than adults with FN. 4,5 Therefore, the results may not be generalizable to an adult cancer population, including the elderly.In addition, the authors admit that the observed rate of bacteremia of 11% was considerably less than that reported by other authors.Importantly, the analysis focused on the 196 FN episodes rather than the 128 individual patients, with 40 patients entered onto this study more than once.The statistical methods used in the analysis are based on an assumption of independence between observations, which can never be assumed when the same patient is included more than once.The authors attempt to justify this approach using a method that does not negate the lack of independence between observations in the same patients.A lack of difference in risk classification, patient characteristics, or outcomes in patients across repeated observations does not represent evidence of independence, particularly in a study of low power.Therefore, the statistical measures and levels of statistical significance reported in this study are invalid.The authors evaluate the test performance of their approach based on the documentation of bacteremia in low-risk and high-risk episodes.However, the appropriate analysis based on the 24 low-risk patients provides a 95% CI on the estimated false-negative rate of 0% to 14%, leaving considerable uncertainty about the safety of this ap-
Killers
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Costs
Authors: WILLIAM A. STEIGER
Journal: Annals of Internal Medicine (1976)

Comments and Correction1 May 1976Medical CostsWILLIAM A. STEIGER, M.D., F.A.C.P.WILLIAM A. STEIGER, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-84-5-610_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: With reference to "Health Care 1976: Costs and Consequences" (Ann Intern Med84:211-212, 1976) may I make two comments? While all that Dr. Herman Somers says is true, it is seldom pointed out that medical insurance and rising medical care costs feed upon each other. Thus the more insurance, the more utilization, thereby increasing the total dollar expenditure. Likewise the higher these expenditures, the more urgent it is to get insurance coverage. National health insurance with all its proposed constraints, review procedures, and quality controls, will increase the total dollar expenditure on health care. Witness Medicare, Medicaid,... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: 1732 Sir William Osler Drive Virginia Beach, VA 23454 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByMicrostructure Investigation of the Spark Plasma Sintered Cu—Al—Ni Shape Memory Material 1 May 1976Volume 84, Issue 5Page: 610-611KeywordsHealth careHealth care utilizationHealth insuranceMedicareQuality improvement Issue Published: 1 May 1976 PDF DownloadLoading ...
Lung scintiscanning
Authors: E. J. Potchen
Journal: JAMA (1968)

The incidence at autopsy of undiagnosed pulmonary emboli amply demonstrates the inadequacy of current diagnostic measures. Physicians alert to this discrepancy have renewed interest in the clinical assessment of regional pulmonary perfusion. The addition of radionuclides to the diagnostic armamentarium affords a supplementary means for the external detection of regional pulmonary function. We now measure regional pulmonary blood flow by two radioisotopic methods. In one, an inert radioactive gas is injected intravenously, and the regional lung perfusion is evaluated with multiple probes or a gamma camera. The isotope rapidly leaves the pulmonary capillaries and diffuses into the alveolar air. Rectilinear scintiscanning is not used, since rapid simultaneous measurements are necessary to distinguish perfusion from alveolar gas exchange. West<sup>1</sup>has recently reviewed these pulmonary-function studies with radioactive gases, and though I acknowledge the significance of ventilatory lung scans as an adjunct to macrocolloid perfusion scanning, space will not permit an
A Synopsis of Anæsthesia
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"ETIOLOGY UNKNOWN"
Authors: MARCUS HAASE
Journal: JAMA (1923)

I doubt seriously whether there is a more humiliating moment in the life of a medical man, either as teacher or practitioner, than when asked by a student or patient, "What is the cause of this?" and he is forced to say, "I do not know." While it is true that few diseases of the skin end fatally, they not infrequently play havoc with the lives of the afflicted. I recall the case of an otherwise beautiful woman whose life was devoted to social service work among the handicapped, the blind and the crippled, who gave up her work and is now living in seclusion because of the marring effect of vitiligo. In another instance, one of the most brilliant young lawyers of our community was forced to withdraw from a promising career in both law and politics, for the same reason. And I have never been able to satisfy
Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma
Authors: A. Cheng, Y. Kang, Z. Chen, C. Tsao, S. Qin, J. Kim, K. Burock, J. Zou, D. Voliotis, Z. Z. Guan
Journal: Journal of Clinical Oncology (2008)

4509 Background: In Asian countries, the incidence of HCC is higher than in Western nations, partly attributed to a greater prevalence in Asia of infection with hepatitis B virus - a major HCC risk factor. Sorafenib (Sor), a multikinase inhibitor with anti-angiogenic and pro-apoptotic activities, significantly increased overall survival (OS) in a randomized, placebo (Pl)-controlled, phase III trial of patients with HCC (SHARP). Here we report efficacy and safety results of a phase III trial of Sor in HCC patients from the Asia-Pacific region. Methods: Patients with advanced, measurable HCC, ECOG PS 0–2, Child-Pugh status A, no prior systemic therapy for HCC, and life expectancy ≥12 wks were randomized 2:1 to Sor 400mg bid or Pl. Endpoints were OS, time to progression (TTP), time to symptomatic progression (FSHI8-TSP), disease control rate (DCR; defined as complete or partial response, or stable disease according to RECIST, maintained for ≥28 days from first demonstration) and safety. No primary endpoint was defined. Results: 226 patients were randomized; Sor n=150, Pl n=76. Baseline characteristics were similar between the two groups (Sor vs Pl): mean age 51±13 vs 52±12 years, males 85 vs 87%. Efficacy results for time-to-event endpoints are shown in the table. DCR was 35% (95% CI 28–44) and 16% (95% CI 8–26) in the Sor and Pl groups. Most frequently reported grade ≥3 drug-related AEs were (Sor vs Pl): hand-foot skin reaction (10.1 vs 0.0%), diarrhea (6.0 vs 0.0%), hyperbilirubinemia (3.4 vs 2.7%) and fatigue (3.4 vs 1.3%). Drug-related serious AEs were observed in 13 (9%) and 1 (1%) patients (Sor vs Pl). Conclusions: Sor significantly prolonged OS and TTP in HCC patients in the Asia-Pacific region compared with Pl, and was well tolerated. These results mirrored those of SHARP, despite Asia-Pacific patients having more advanced disease based on ECOG PS, number of tumor sites and lung metastases. These findings confirm the survival advantage of Sor, and demonstrate its broad applicability in Asian patients with advanced HCC. Efficacy Endpoints Endpoint Events (n [%], Sor vs Pl) HR (95% CI) Median (months, Sor vs Pl) p-value (log-rank) OS 102 (68) vs 62 (82) 0.67 (0.49–0.93) 6.2 vs 4.1 0.0155 TTP 108 (72) vs 58 (76) 0.58 (0.42–0.80) 2.8 vs 1.4 0.0007 FSHI8-TSP 126 (84) vs 65 (86) 0.89 (0.66- 1.20) 3.5 vs 3.4 0.4458 PFS 134 (89) vs 73 (96) 0.62 (0.46–0.83) 2.8 vs 1.4 0.0009 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bayer, Bayer Schering Pharma Bayer, Pfizer Oncology Bayer AG Bayer, Pfizer Oncology Bayer
Pitfalls in interpreting serum creatine phosphokinase activity
Authors: M. A. Nevins
Journal: JAMA (1973)

Although elevated serum creatine phosphokinase (CPK) activity is a sensitive indicator of myocardial necrosis, abnormal values may occur in a variety of extracardiac disorders. Fifty-two of 100 consecutive patients admitted to a short-term medical ward had elevated CPK activity; 26 of them had more than twice normal. Increased physical activity and intramuscular injections should be considered as potential etiologic factors of abnormal CPK levels in patients with chest pain, particularly when the electrocardiogram and other serum enzymes are not confirmatory. It is hazardous to diagnose myocardial necrosis on the basis of an isolated CPK elevation in the absence of other suggestive evidence. With the development of tissue-specific CPK isoenzymes, however, the clinical usefulness of this test may be enhanced.
Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma.
Authors: Joshua Ryan Richter, Carl Ola Landgren, John S. Kauh, Jonathan Back, Yacine Salhi, Venkateshwar Reddy, Eliel Bayever, Jesus G. Berdeja
Journal: Journal of Clinical Oncology (2018)

TPS3132 Background: Therapeutic advances have improved outcomes in multiple myeloma but patients eventually relapse, requiring treatment with agents that are active in refractory disease. CD38, a transmembrane glycoprotein upregulated on myeloma cells, is a validated disease target as evidenced by the anti-myeloma activity of daratumumab, an anti-CD38 human IgG1κ monoclonal antibody. However, not all patients respond and many eventually develop progressive disease to daratumumab monotherapy.1 GBR 1342, a CD3xCD38 bispecific antibody engineered (using Glenmark's BEAT platform) to direct T-cells to CD38-expressing myeloma cells, has the potential to overcome the limitations of existing therapies. In preclinical studies, GBR 1342 redirected the cytotoxic potential of T-cells to human myeloma cell lines in vitro and in mouse xenograft models. This ongoing, 2-part, first-in-human study aims to: (1) evaluate the safety and maximum tolerable dose (MTD) of GBR 1342 monotherapy in subjects with relapsed/refractory multiple myeloma ( > 3 prior therapies); and (2) further elucidate the safety, tolerability, and preliminary clinical activity of GBR 1342 at the MTD. Methods: In Part 1, intravenous GBR 1342 is administered on Days 1 and 15 in 28-day treatment cycles at escalating doses (Table). The first 4 cohorts consist of a single subject. Subsequent cohorts use a 3+3 enrollment design. In Part 2, 65 evaluable subjects will be treated at the MTD identified in Part 1 until disease progression or unacceptable toxicity occurs. Primary endpoints include AEs (frequency, severity), number of dose-limiting toxicities during Cycle 1 (Part 1), and objective response to GBR 1342 (Part 2). Secondary endpoints include pharmacokinetics and anti-tumor activity of GBR 1342 (progression-free and overall survival). 1Nijhof IS et al. Blood 2016; doi.org/10.1182. Clinical trial information: NCT03309111.Dose escalation scheme (doses in ng/kg). Cohort Cycle 1 Cycle 2 Subsequent Cycle(s) Day 1 Day 15 Day 1 Day 15 Day 1 Day 15 Single Subject 1 1 3 3 3 3 3 2 3 10 10 10 10 10 3 10 30 30 30 30 30 4 30 60 60 60 60 60 3+3 5 60 100 100 100 100 100 6 100 200 200 200 200 200 7 200 400 400 400 400 400 8 400 600 600 600 600 600 9 600 800 800 800 800 800 10 800 1000 1000 1000 1000 1000
Erythrocyte Pyruvate Kinase Deficiency Resulting in Congenital Nonspherocytic Hemolytic Anemia
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Journal of Anatomy, London
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acute onset of dyspnea associated with colonoscopy
Authors: J. R. Dexter
Journal: JAMA (1980)

WE PRESENT this case to demonstrate that the increase in abdominal pressure associated with colonoscopy may result in visceral herniation through a chronic diaphragmatic defect. <h3>Report of a Case</h3> A 67-year-old man was referred for colonoscopy because a sigmoid polyp had been demonstrated by barium enema examination. He was otherwise in good health and denied previous illness or injury except for blunt upper abdominal trauma and several rib fractures during an automobile accident in 1939. Subsequent chest roentgenograms had shown an elevated right hemidiaphragm. During the colonoscopy, a 1.5-cm polyp on a long stalk was transected from the sigmoid colon with electrocautery. Shortly thereafter, the patient complained of sudden dyspnea and asked to sit up. Breath sounds were diminished in the right hemithorax. The abdomen was moderately distended but nontender, and the liver was palpable 7 cm below the costal margin. Initially, bowel sounds were absent but were later noted
Earthquake-Associated Deaths—California
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prognostic Uncertainties in Cerebral Vascular Disease
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal